A Phase 2b / 3 Multicenter Randomized Double-blind Placebo-controlled Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
The purpose of this research study is to see if CSL300 (Clazakizumab) is effective and safe in patients on maintenance dialysis at reducing the risk of dying from heart-related events or having a heart attack.
A Phase 2b Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes
The purpose of this study is to investigate the safety of the investigational drug (LY3437943) in the kidney, and how well it works to help participants obesity or overweight with chronic kidney disease. The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How LY3437943 compares to placebo in helping people with obesity or overweight and chronickidney disease with or without Type 2 Diabetes Mellitus (T2DM). The safety of LY3437943 and any side affects you might have when you take it.
A Phase 2b Randomized Double-blind Placebo-controlled Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer
This trial is designed to evaluate efficacy and psychological mechanisms of single-dose psilocybin-assisted psychotherapy (PAP) to treat psychiatric (anxiety, depression) and existential distress (demoralization, death anxiety), and quality-of-life (QOL), in 200 outpatients with late-stage or advanced cancer. The study will assess the strength and durability of therapeutic effects in a double-blind, parallel-design, placebo-controlled, two-center RCT comparing a single 25mg oral ‘high’ dose of psilocybin to a single 100mg dose of niacin (active placebo), both delivered in conjunction with a psychotherapy platform.
A Phase 3 Multi-center Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
To evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH compared with placebo as measured by the OHSA composite score over a double-blind, RW period of 8 weeks following an OL period of 12 weeks.This study includes 4 periods: Screening, OL, RW, and Long-Term Treatment Extension (LTE). Screening is approximately 14 days. The OL and RW periods of the study are a Phase 3, multi-center, RW study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. Approximately 102 participants will be enrolled such that at least 72 participants continue into the RW period. The LTE period is to evaluate the safety and tolerability of ampreloxetine in participants with MSA and symptomatic nOH over 104 weeks.
A Phase 3 Randomized Double-Blind Multicenter Study to Evaluate the Efficacy Safety and Tolerability of Psilocybin in Adults with Major Depressive Disorder
The purpose of this research study is to see if the investigational drug, psilocybin, can help people with major depressive disorder (MDD). This clinical trial s designed to evaluate the safety and efficacy of psilocybin 25 mg versus placebo in adult participants with major depressive disorder (MDD) who are experiencing a depressive episode of at least a 60-day duration. Participants will be randomly assigned to receive a single oral dose of psilocybin 25 mg, psilocybin 5 mg, or inactive placebo, administered with psychosocial support.
A Phase 3 Randomized Double-blind Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II IIIA IIIB (N2) Non-small Cell Lung Cancer
This clinical study will evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II to IIIB (N2) NSCLC.
A Phase 3 Randomized Double-Blind Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis
This trial is testing MK-7240 in people with moderate to severely active ulcerative colitis (UC). This trial will compare MK-7240 to placebo. A placebo looks like a trial drug, but it has no active ingredients. The purpose of this trial is to: Test the safety of the trial drug, MK-7240 See how well the trial drug works compared to placebo
A Phase 3 Randomized Double-Blind Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn s Disease
This trial is testing an experimental drug tulisokibart (MK-7240) in people with moderately to severely active Crohn’s disease (CD). This trial will compare tulisokibart to placebo. A placebo looks like a trial drug, but it has no active ingredients. The purpose of this trial is to test the safety of the trial drug, tulisokibart, and see how well tulisokibart works, compared to placebo, The trial drug you get will depend on which group you are placed in. Study 1 has 4 groups: Groups 1, 2, and 3 will get different doses of tulisokibart. Group 4 will get placebo only.
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
The purpose of this study is to evaluate the safety and efficacy (how well something works) of EFX in people with NASH/MASH. NASH/MASH is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD). EFX is an investigational drug, meaning it is being tested in this research study and is not Food and Drug Administration (FDA) approved to treat this condition.
A Phase 3 Randomized Double-blind Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome (PWS)
This research study is being done to see if a new drug called ARD-101 can help treat people with hyperphagia due to PWS.